VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
QTTB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
QTTBQ32 Bio Inc.
$13.62$174M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksQTTBP/E History

QTTB logoQ32 Bio Inc. (QTTB) P/E Ratio History

Expensive

Trading at 5.6x vs 5Y avg 1.9x · 100th percentile · Material premium to history · Data 2025–2026

Current P/E (TTM)
5.6x
+192% vs 5Y avg
5Y Avg P/E
1.9x
Median 2.4x
5Y Percentile
100th
Upper end of range
PEG Ratio
N/A
5-Year P/E Range
5.6x
Min1.4xMedian2.4xMax2.4x
TTM EPS$2.36
Price$13.62
Earnings Yield17.77%
EPS Growth (1Y)136.8%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of July 8, 2026, Q32 Bio Inc. (QTTB) trades at a price-to-earnings ratio of 5.6x, with a stock price of $13.62 and trailing twelve-month earnings per share of $2.36.

The current P/E is 192% above its 5-year average of 1.9x. Over the past five years, QTTB's P/E has ranged from a low of 1.4x to a high of 2.4x, placing the current valuation at the 100th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.4x, QTTB trades at a 76% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.

Relative to the broader market, QTTB trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our QTTB DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

QTTB Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
5.6vs23.4
-76%
Below Sector
vs. S&P 500
5.6vs25.9
-78%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 137% EPS growth (1Y)

QTTB P/E vs Peers

Immunology and Inflammation Therapies peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ALNY logoALNYAlnylam Pharmaceuticals, Inc.
$43B138.0-+207%Best
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$70B16.3Lowest2.58Best+8%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

QTTB Historical P/E Data (2025–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$6.42$2.662.4x+25%
FY2025 Q4Dec 31 2025$3.32$2.301.4x-25%

Average P/E for displayed period: 1.9x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

1+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

QTTB — Frequently Asked Questions

Quick answers to the most common questions about buying QTTB stock.

What is QTTB's P/E ratio?

Q32 Bio Inc. (QTTB) trailing twelve-month P/E ratio is 5.6x, based on TTM diluted EPS of $2.36. The 5-year average P/E is 1.9x and the historical range spans 1.4x to 2.4x.

Is QTTB stock overvalued or undervalued?

QTTB trades at 5.6x P/E, above its 5-year average of 1.9x. The 100th percentile ranking within the 1.4x–2.4x historical range indicates a premium to historical valuation.

Is QTTB stock expensive?

Yes, QTTB is expensive relative to its own history. The current P/E of 5.6x is above the 5-year average of 1.9x. The stock sits at the 100th percentile of its 5-year valuation range.

What is QTTB's historical P/E range?

Over the past 5 years, QTTB's P/E ratio has ranged from 1.4x to 2.4x, with a median of 2.4x and an average of 1.9x. The current P/E of 5.6x places the stock at the 100th percentile of this range. Full historical data spans 2025–2026.

How does QTTB's P/E compare to the S&P 500?

QTTB trades at 5.6x P/E versus the S&P 500 median of 25.9x. The 78% discount to the market suggests lower growth expectations or perceived higher risk.

How does QTTB's valuation compare to Healthcare peers?

Q32 Bio Inc. P/E of 5.6x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is QTTB's PEG ratio?

QTTB PEG ratio is N/A, based on a P/E of 5.6x and EPS growth of 136.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is QTTB's earnings yield?

QTTB earnings yield is 17.77%, the inverse of its 5.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

QTTB P/E Ratio History (2025–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current2.4x
Period Avg1.9x
Range1.4x - 2.4x
Change+67%
2 quartersDec 31, 2025 - Mar 31, 2026